Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Equivalents (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash & Equivalents for 4 consecutive years, with $197.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 57.7% to $197.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.1 million through Dec 2025, up 57.7% year-over-year, with the annual reading at $197.1 million for FY2025, 57.7% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $197.1 million at Day One Biopharmaceuticals, up from $43.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $422.8 million in Q3 2024, with the low at $33.4 million in Q1 2025.
  • Average Cash & Equivalents over 4 years is $183.5 million, with a median of $193.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 448.82% in 2024, then plummeted 89.76% in 2025.
  • Over 4 years, Cash & Equivalents stood at $85.3 million in 2022, then skyrocketed by 170.68% to $230.8 million in 2023, then plummeted by 45.85% to $125.0 million in 2024, then skyrocketed by 57.7% to $197.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $197.1 million, $43.3 million, and $35.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.